Emergent Biosolutions Stock Today

EBS Stock  USD 9.27  0.70  7.02%   

Performance

1 of 100

 
Weak
 
Strong
Weak

Odds Of Distress

Less than 46

 
High
 
Low
About Average
Emergent Biosolutions is selling for under 9.27 as of the 14th of November 2024; that is 7.02 percent decrease since the beginning of the trading day. The stock's lowest day price was 9.26. Emergent Biosolutions has 46 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Emergent Biosolutions are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 15th of October 2024 and ending today, the 14th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
15th of November 2006
Category
Healthcare
Classification
Health Care
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. The company has 54.18 M outstanding shares of which 6.95 M shares are currently shorted by investors with about 5.21 days to cover. More on Emergent Biosolutions

Moving against Emergent Stock

  0.48DOMH Dominari HoldingsPairCorr
  0.48DTIL Precision BioSciencesPairCorr
  0.42ME 23Andme HoldingPairCorr
  0.36DRTS Alpha Tau MedicalPairCorr
  0.32VCNX VaccinexPairCorr

Emergent Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentJoseph Papa
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, Austrian Traded Index, HNX MidSmall Cap, ATX Prime, HNX, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.870.5755
Way Up
Slightly volatile
Total Current Liabilities683.9 M651.3 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total394.8 M522.6 M
Way Down
Slightly volatile
Total Assets1.2 B1.8 B
Way Down
Slightly volatile
Total Current Assets530.3 M679.5 M
Significantly Down
Slightly volatile
Debt Levels
Emergent Biosolutions can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Emergent Biosolutions' financial leverage. It provides some insight into what part of Emergent Biosolutions' total assets is financed by creditors.
Liquidity
Emergent Biosolutions has 860.2 M in debt with debt to equity (D/E) ratio of 0.56, which is OK given its current industry classification. Emergent Biosolutions has a current ratio of 3.84, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Emergent to invest in growth at high rates of return.

Depreciation

131.35 Million
Emergent Biosolutions (EBS) is traded on New York Stock Exchange in USA. It is located in 400 Professional Drive, Gaithersburg, MD, United States, 20879 and employs 1,600 people. Emergent Biosolutions is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 540.22 M. Emergent Biosolutions runs under Biotechnology sector within Health Care industry. The entity has 54.18 M outstanding shares of which 6.95 M shares are currently shorted by investors with about 5.21 days to cover. Emergent Biosolutions has about 642.6 M in cash with (206.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.28.
Check Emergent Biosolutions Probability Of Bankruptcy
Ownership Allocation
Emergent Biosolutions holds a total of 54.18 Million outstanding shares. Over half of Emergent Biosolutions' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Emergent Ownership Details

Emergent Stock Institutional Holders

InstituionRecorded OnShares
Jpmorgan Chase & Co2024-06-30
649.5 K
Goldman Sachs Group Inc2024-06-30
611 K
Two Sigma Advisers, Llc2024-06-30
575.4 K
Geode Capital Management, Llc2024-06-30
556.2 K
Bank Of America Corp2024-06-30
554.9 K
Carronade Capital Management Lp2024-06-30
550.6 K
Marshall Wace Asset Management Ltd2024-06-30
542.8 K
Jane Street Group Llc2024-06-30
490.8 K
Aqr Capital Management Llc2024-06-30
460.3 K
Blackrock Inc2024-06-30
3.8 M
Vanguard Group Inc2024-06-30
3.7 M
View Emergent Biosolutions Diagnostics

Emergent Biosolutions Historical Income Statement

At this time, Emergent Biosolutions' Depreciation And Amortization is comparatively stable compared to the past year. Interest Expense is likely to gain to about 92.3 M in 2024, despite the fact that Operating Income is likely to grow to (690.1 M). View More Fundamentals

Emergent Stock Against Markets

Emergent Biosolutions Corporate Directors

Sue BaileyIndependent DirectorProfile
Jerome HauerIndependent DirectorProfile
Kathryn ZoonIndependent DirectorProfile
Seamus MulliganDirectorProfile

Additional Tools for Emergent Stock Analysis

When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.